Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).

Fiche publication

Date publication

juillet 2025

Journal

Annals of hematology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre

Tous les auteurs :
Quinquenel A, Leprêtre S, Dilhuydy MS, Bussot L, Marjanovic Z, Benbrahim O, Guièze R, Santogostino A, Dartigeas C, Feugier P, Roos-Weil D, Damaj G, Laribi K, Ysebaert L, Levy V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40736551

Résumé

Acalabrutinib is a second-generation BTK inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) after demonstrating efficacy and safety in clinical trials. NAOS, a real-world study, complements these trials with real-world (rw) acalabrutinib data generated from clinical practice. This retrospective, non-interventional, longitudinal study was conducted in 59 sites in France in adult patients initiating acalabrutinib for CLL in 2021-2022.The study assessed rw use (time to discontinuation, TTD) and effectiveness (rw progression free survival, rwPFS) in first line (L1) and relapsed/refractory setting (L2+). At the time of the analysis, data were collected from routine medical records since the treatment start up to the end of 2022. Of the 485 enrolled patients, 58.8% were in L1 and 41.2% in L2+. Median age was 73 (L1) and 77 (L2+) years. Of them, 55.1% had a prior cardiovascular history, 25.1% del(17p)/TP53m, and 67.4% were uIGHV. Among 188 patients initiated in 2021 (119 L1; 69 L2+), 31.4% discontinued treatment, 14.9% of whom due to adverse event (AE). The 12-month rwPFS rate was 93.1% (88.5-97.7) in L1 and 87% (79.0-94.9) in L2 + patients with no significant difference based on del17p/TP53m (p = 0.21) and on IGHV status (p = 0.34). AEs leading to treatment changes occurred in 40 patients (21.3%), grade 3/4 AE in 9.6%, while cardiac disorders occurred in only 2.1% of patients. NAOS, one of the largest real-world cohorts of acalabrutinib-treated CLL patients in Europe, showed effectiveness and safety consistent with clinical trials, despite an older population with more cardiovascular comorbidities.